Valiant Laboratories IPO GMP, review, Price, Date, Allotment

Valiant Laboratories ipo Review: Valiant Laboratories is coming up with its Initial Public Offering

Valiant Laboratories IPO- About The Company

 

valiant Laboratories Limited is an Active Pharmaceutical Ingredient (“API”) / Bulk Drug manufacturing company having focus on manufacturing of Paracetamol. The company manufacture Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of their customers.

The company’s manufacturing unit is located in Palghar, Maharashtra, spread across 2,000 sq. mts. of land with an aggregate annual total installed capacity of 9,000 MT per annum. Valiant Laboratories also has an R&D Facility, equipped with an analytical laboratory and infrastructure for developmental activities in existing products.

Valiant Laboratories Limited imports Para Amino Phenol, being the raw material for the manufacture of Paracetamol from China and Cambodia.

As of April 30, 2023, Valiant Laboratories has 86 employees.

 

more information please check – https://www.bseindia.com/corporates/download/332412/ValiantLaboratoriesLimitedDRHP_20230614133108.pdf

 

Valiant Laboratories IPO- industry overview 

 

The paracetamol API industry (Domestic consumption+ exports) grew from Rs. 22 billion in fiscal 2017 to Rs.39 billion in fiscal 2023.The paracetamol API market growth was mainly supported by growth in pain and analgesics therapy area which focuses on treatment of common fever, cough and cold as well as volume rise coupled with strong realization levels for players. The paracetamol API demand saw uptick in fiscal 2022 owing to pent up demand due to covid-19 and extensive usage of common cold and fever drugs during the second wave of covid-19. Also, the boost in export demand due to supply restrictions in China gave opportunities for Indian manufacturers to tap the potential export market

. Some of the paracetamol API based products saw huge demand during the pandemic giving rise to the strong demand in the domestic market. Increased sales of these fever medicines saw demand for domestically manufactured APIs in fiscal 2021 and fiscal 2022.The past growth in the paracetamol API has been supported by moderate increase in the volume consumption coupled with the price rise.

 Going forward the paracetamol API industry is expected to clock a CAGR of 5-7% between fiscal 2023 and fiscal 2027, largely driven by the demand from domestic formulation manufacturers as well as export markets

 

Object Of The Issue

 

  • Investment in its wholly-owned subsidiary, Valiant Advanced Sciences Private Limited (VASPL) for part-financing its capital expenditure requirements in relation to the setting up of a manufacturing facility for specialty chemicals at Saykha Industrial Area, Bharuch, Bharuch, Gujarat (Proposed Facility);
  • Investment in VASPL for funding its working capital requirements; and
  • General corporate purposes.

 

 

Valiant Laboratories Financial Performance

 

  FY 2021 FY 2022 FY 2023
Revenue 82.38 209.14 333.91
Expenses 72.04 179.73 300.64
Net income 4.75 22.59 29.03
Margin (%) 5.77 10.80 8.69

INR CR.

Valiant Laboratories Valuations & Margins

 

FY 2021 FY 2022 FY 2023
EPS 10.83 9.52 8.91
PE ratio
RONW (%) 34.54 38.48 28.86
NAV 30.86
ROCE (%) 70.86 35.75 22.76
EBITDA (%) 27.42 14.52 10.51
Debt/Equity 0.00 0.85 0.59

 

Valiant Laboratories IPO Peer Comparison

S. No. Face Value Company Name PE
1 1 Granules India Ltd 13.19
2 1 Jagsonpal Pharmaceuticals Limited 36.03

 

Valiant Laboratories ipo – strengths 

 

  • Experienced promoters and strong management team.
  • Strong Focus on Sustainability in Operations.
  • Strategically located manufacturing facility.
  • Quality-Focused Compliant Manufacturing and R&D Infrastructure.
  • Reducing dependence on import of raw materials.

 

ALSO READ –

Signature Global IPO GMP, review, Price, Date, Allotmen

Updater Services IPO GMP, review, Price, Date, Allotment

 

Valiant Laboratories IPO Details

 

Valiant Laboratories IPO Dates 27 Sep – 3 Oct 2023
Valiant Laboratories IPO Price Coming soon
Fresh issue 11,556,000 shares
Offer For Sale NIL
Total IPO size 11,556,000 shares
Minimum bid (lot size) Coming soon
Face Value  INR 10 per share
Retail Allocation 35%

 

Valiant Laboratories IPO Dates & schedule 

 

Valiant Laboratories IPO Opening Date 27 September 2023
Valiant Laboratories IPO Closing Date 3 October 2023
Finalization of Basis of Allotment 6 October 2023
Initiation of refunds 9 October 2023
Transfer of shares to demat accounts 10 October 2023
Valiant Laboratories IPO Listing Date 11 October 2023

 

Valiant Laboratories IPO GMP Today

 

Date Ipo gmp  Kostak Subject to Sauda
Coming soon

 

Valiant Laboratories IPO Allotment Status

Valiant Laboratories IPO allotment will be available on Link Intime’s website. Click on this link to get allotment status.

 

 

 

1 thought on “Valiant Laboratories IPO GMP, review, Price, Date, Allotment”

Leave a Comment